Details for Patent: 10,125,369
✉ Email this page to a colleague
Which drugs does patent 10,125,369 protect, and when does it expire?
Patent 10,125,369 protects LEQVIO and is included in one NDA.
This patent has fifty-nine patent family members in thirty-one countries.
Summary for Patent: 10,125,369
| Title: | PCSK9 iRNA compositions and methods of use thereof |
| Abstract: | The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia. |
| Inventor(s): | Anna Borodovsky, Kallanthottathil G. Rajeev, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana KUCHIMANCHI, Muthiah Manoharan, Stuart Milstein |
| Assignee: | Alnylam Pharmaceuticals Inc |
| Application Number: | US14/650,128 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,125,369 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 10,125,369
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | 10,125,369 | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | 10,125,369 | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| Novartis | LEQVIO | inclisiran sodium | SOLUTION;SUBCUTANEOUS | 214012-001 | Dec 22, 2021 | RX | Yes | Yes | 10,125,369 | ⤷ Start Trial | Y | Y | AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF ADULTS WITH HYPERCHOLESTEROLEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,125,369
| PCT Information | |||
| PCT Filed | December 05, 2013 | PCT Application Number: | PCT/US2013/073349 |
| PCT Publication Date: | June 12, 2014 | PCT Publication Number: | WO2014/089313 |
International Family Members for US Patent 10,125,369
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2929031 | ⤷ Start Trial | 301107 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2929031 | ⤷ Start Trial | PA2021510 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2929031 | ⤷ Start Trial | 2021C/520 | Belgium | ⤷ Start Trial |
| European Patent Office | 2929031 | ⤷ Start Trial | 16/2021 | Austria | ⤷ Start Trial |
| European Patent Office | 2929031 | ⤷ Start Trial | LUC00209 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2929031 | ⤷ Start Trial | CA 2021 00016 | Denmark | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
